patients for each antiplatelet arm) now provides strong confirmatory evidence. (RR = 0.779; CI = 0.629-0966; p = 0.022) for the endpoint of non-fatal stroke or death from any cause (the available endpoint closest to an 'any stroke' outcome, as defined in table 1 of the editorial [1] ). The stroke or death outcomes for published randomized trials of dipyridamole plus aspirin vs. aspirin alone, and our meta-analysis are provided in table 1 .
In addition to the citations in the editorial's text, data from and references for these studies may also be found in the antiplatelet trialists' papers [3, 4] . Values in bold signify p < 0.05. A = Aspirin; D = dipyridamole; ER = extended release; Hy = hydergine; RR = relative risk of stroke among patients randomized to the 1st vs. the 2nd regimen.
a ESPRIT: non-fatal stroke, or vascular death. b Used by 83% of those on D+A.
